Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | JBIO | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | 3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.40 |
|
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade’s pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sofinnova Investments, Inc. | 31 Dec 2024 | 107,386 |
| Braidwell Lp | 31 Dec 2024 | 41,155 |
| Logos Global Management Lp | 31 Dec 2024 | 39,998 |
| Allostery Investments Lp | 31 Dec 2024 | 24,304 |
| Affinity Asset Advisors, Llc | 31 Dec 2024 | 22,856 |
| Blackstone Inc. | 31 Dec 2024 | 14,273 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 93.80 | - | 1,062,326 | 99,646,179 |
| Aggregate Net Quantity | 1,062,326 | |||
| Aggregate Net Value ($) | 99,646,179 | |||
| Aggregate Avg. Buy ($) | 93.80 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 28 Apr 2025 | Acquired (+) | 1,062,326 | 93.80 | 99,646,179 |
| Date | Type | Details |
|---|---|---|
| 21 Apr 2025 | Announcement | Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals |
| 09 Apr 2025 | Announcement | Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences |
| 07 Apr 2025 | Announcement | Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |